Aliskiren-associated acute renal failure with hyperkalemia

Clinical Nephrology

Volumn 71, Issue 3, 2009, Pages 326-328

  Venzin, R M ^a   Cohen, C D ^a   Maggiorini, M ^a   Wüthrich, Rudolf P ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Acute renal failure; Aliskiren; Direct renin inhibitor; Hyperkalemia

Indexed keywords

ALISKIREN; AMLODIPINE; BICARBONATE; CREATININE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; SODIUM; SPIRONOLACTONE; TORASEMIDE; AMIDE; ANTIHYPERTENSIVE AGENT; FUMARIC ACID DERIVATIVE;

ACUTE KIDNEY FAILURE; AGED; ANKLE EDEMA; ARTICLE; BLOOD PRESSURE; BRADYCARDIA; CASE REPORT; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG WITHDRAWAL; DYSPNEA; ECHOGRAPHY; FATIGUE; FEMALE; HEART ATRIUM FIBRILLATION; HEMODIAFILTRATION; HUMAN; HYPERKALEMIA; HYPERTENSION; INTENSIVE CARE; KIDNEY FUNCTION; LEUKOCYTOSIS; METABOLIC ACIDOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PULSE RATE; SIDE EFFECT; SODIUM URINE LEVEL; CHEMICALLY INDUCED DISORDER; RENAL REPLACEMENT THERAPY;

AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; FEMALE; FUMARATES; HUMANS; HYPERKALEMIA; HYPERTENSION; KIDNEY FAILURE, ACUTE; RENAL DIALYSIS;

EID: 65449168731     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71326     Document Type: Article

References (8)

1. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005; 111: 1012-1018.
2. Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov. 2008; 7: 399-410.
3. O'Brien E, Barton J, Nussberger J et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension. 2007; 49: 276-284.
4. Oparil S, Yarows SA, Patel S, Fang H, Zhang J and Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet. 2007; 370: 221-229.
5. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008; 358: 2433-2446.
6. Shafiq MM, Menon DV, Victor RG. Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug. Am J Med. 2008; 121: 265-271.
7. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003; 42: 1137-1143.
8. Weir MR, Bush C, Anderson DR, Zhang J, Keefe D, Satlin A. Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens. 2007; 1: 264-277.